Lack of Bub2 GAP activity leads to persistent symmetric localization of Bub2 on SPBs. (A, B, and D) Bacterially expressed GST-Bub2, MBP-Bfa1, and 6×His-Tem1 were used in in vitro GAP assays as previously described (Geymonat et al., 2002). In brief, 240 nM of 6×His-Tem1 was loaded with γ-[32P]GTP in either the absence or presence of 150 nM MBP-Bfa1 and incubated at 30°C for 10 min. The mixture was then added to 15 μM of GST-Bub2 or buffer alone, and kinetics of GTP hydrolysis and dissociation was followed by filter binding assays (see Materials and methods). (C) Increasing amounts of the indicated Bub2 variants (0:1, 1:1, 2:1, 2.6:1, 6.6:1, 13:1, 26:1, 53:1, and 80:1 molar ratio Bub2/Bfa1) were added to 605 nM of 6×His-Tem1– γ-[32P]GTP in the presence of 378 nM MBP-Bfa1 (final concentrations), and the fraction of filter-bound radioactivity was measured after 8 min. (E) Localization of Bub2R85A-HA3 at anaphase SPBs was monitored by in situ immunostaining with anti-HA antibodies. (F) Localization of Bfa1-HA6 in asynchronous BUB2R85A-myc9 cells was monitored as in E. (G, top) Protein extracts from BUB2-myc9 (ySP710), bub2R85A-myc9 (ySP4696), BUB2-myc9 BFA1-HA6 (ySP5087), and two different bub2R85A-myc9 BFA1-HA6 strains (ySP5118 and ySP5119) were used for Western blot analysis of either the total levels of Bub2-myc9 and Bfa1-HA6 (total) or the amount of Bub2-myc9 coimmunoprecipitating with Bfa1-HA6 (anti-HA IP). (bottom) Protein extracts from BFA1-HA6 (ySP2035), BUB2-myc9 BFA1-HA6 (ySP5087), and two different bub2R85A-myc9 BFA1-HA6 strains (ySP5118 and ySP5119) were used for Western blot analysis of either the total levels of Bub2-myc9 and Bfa1-HA6 (total) or the amount of Bfa1-HA6 coimmunoprecipitating with Bub2-myc9 (anti-myc IP).